Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Vincenzi, Bruno ^a   Napolitano, Andrea ^a   Zoccoli, Alice ^a   Iuliani, Michele ^a   Pantano, Francesco ^a   Papapietro, Nicola ^a   Denaro, Vincenzo ^a   Santini, Daniele ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bisphosphonates; Osteonecrosis of the jaw; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; VASCULOTROPIN; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; DIAGNOSTIC VALUE; DRUG MEGADOSE; EARLY DIAGNOSIS; HUMAN; JAW OSTEONECROSIS; KIDNEY CANCER; MAJOR CLINICAL STUDY; MANDIBLE; PREDICTION; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SERUM; VASCULOTROPIN BLOOD LEVEL;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; HUMANS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866173120     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-56     Document Type: Article

References (7)

1. Epidemiology and pathogenesis of osteonecrosis of the jaw. Reid IR, Cornish J, Nat Rev Rheumatol 2011 8 90 96 22124271
2. Osteonecrosis of the jaw related to bevacizumab. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM, J Clin Oncol 2008 26 4037 4038 10.1200/JCO.2007.15.5424 18711196
3. Bevacizumab-associated osteonecrosis of the jaw. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B, Ann Oncol 2008 19 2091 2092 10.1093/annonc/mdn653 18977851
4. Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw. Yin G, Bai Y, Luo E, Med Hypotheses 2011 76 347 349 10.1016/j.mehy.2010.10.036 21074946
5. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G, Clin Cancer Res 2003 9 2893 2897 12912933
6. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G, Clin Cancer Res 2002 8 1080 1084 12006522
7. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Santini D, Vincenzi B, Tonini G, Scarpa S, Baldi A, Clin Cancer Res 2003 9 3215 author reply 3216 12912976